Video

HER2-Amplified Colorectal Cancer: Clinical Trial Data

Author(s):

Tanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Related Videos
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Shaji Kumar, MD
Shaji Kumar, MD
Related Content
Aparna Parikh, MD
December 22nd 2024

Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC

Binod Dhakal, MD, associate professor, medicine, Division of Hematology, Medical College of Wisconsin; Muhamed Baljevic, MD, associate professor, medicine, Division of Hematology Oncology, director, Plasma Cell Disorders Research, director, Vanderbilt Amyloidosis Multidisciplinary Program, co-chair, Protocol Review and Monitoring System, disease team lead, plasma cell dyscrasias and lymphomas, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
December 6th 2024

How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Cathy Eng, MD, FACP, FASCO
December 6th 2024

NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC

Peter Martin, MD
December 2nd 2024

BTK Inhibitor–Based Combinations Represent the Future of MCL Management